Skip to main content
. 2020 Oct 15;6(12):1971–1972. doi: 10.1001/jamaoncol.2020.4749

Figure. Kaplan-Meier Plot of Recurrence-Free Survival According to Continuous vs Interrupted Trastuzumab.

Figure.

Recurrence-free survival was assessed in a landmark analysis from 12 months after the start date of trastuzumab for the continuous and interrupted groups. The median cumulative dose of trastuzumab received was 108 (interquartile range [IQR], 104-110) mg/kg in the continuous group and 81 (IQR, 44-98) mg/kg in the interrupted group.